Support. Daniel Grau, an experienced biotech entrepreneur and operating executive, currently serves as CEO and Director at Avilar Therapeutics, a leading extracellular protein degradation company. Josh holds a BS in Genetics, Genomics, and Biotechnology with a Minor in Business from Brigham Young University. Sadik Kassim is a scientist and executive with extensive experience in the biotechnology industry with a specific focus on cell and gene therapy bioprocessing and translational research. Prior to management consulting, Mr. Grau was Director of Marketing & Business Development at a clinical information technology startup. Peter Kolchinsky - Managing Partner - RA Capital Management, LP - LinkedIn In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Michael conducts due diligence on biotechnology companies at RA Capital. Alex has a BS in Chemistry and a Minor in Religious Studies from Davidson College. Tess has a BA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada. Ally coached Women's Lacrosse at Muhlenberg College in PA. She is on the Steering Committee for No Patient Left Behind, a non-profit focused on reforming American healthcare to make medicines affordable to patients and promote innovation. Peyman Hosseinchi is an Associate within the TechAtlas division of RA Capital Management. Generali's No.3 investor Caltagirone withholds backing for 2022 accounts -sources, Musk says Tesla likely to launch full self-drive technology 'this year', Exclusive: JPMorgan employees gripe about Dimon's return-to-office edict, SpaceX rocket explosion illustrates Elon Musk's 'successful failure' formula, Cucinelli posts 33% rise in Q1 sales, confirms 2023 revenue growth forecast, Exclusive-Peter Thiel, Republican megadonor, won't fund candidates in 2024 - sources, Virginia Governor Youngkin 'humbled' by talk of possible presidential run, European Midday Briefing: Mood Brighter After -2-, Tim Cook unveils new Apple store in India, Morgan Stanley's dealmaking CEO Gorman signals more transactions to come, RA Capital Management LP (Private Equity). Peter Kolchinsky Founder and CEO RA Capital Management. As political refugees, the family was placed in Milwaukee, then Pittsburgh. Most recently he served as Chief Operating Officer at Sage Therapeutics leading all the business functions (commercial, medical affairs, government affairs, business development, technical operations, strategy and program management) and G&A functions. Jessica manages RA's Innovator Resources and co-founded RApport, our biotech communications platform. Peter Kolchinsky | Greenwich Economic Forum Megan Lipcsey is an Associate with the TechAtlas division of RA Capital Management. He holds a BA in Environmental Engineering from Dartmouth College (1998), an MA in International Finance and Energy Policy from John Hopkins University (2008), an MS in Materials Science from Columbia University (2012), and a Masters of Strategic Studies from the Army War College (2020). Prior to these companies, James held senior research leadership roles in the gene and stem cell therapy companies Cell Genesys, Phylogix, and Somatix Therapy. Peyman holds a dual B.S. Ryan Russell is a Fund Accountant at RA Capital Management. Kate previously served as Health Law Assistant at Mintz. Largest investment: 7.9 million shares of Vor Biopharma worth $142 million at the time of its IPO . Peter Pan & Wendy review - Jude Law has fun in a so-so reinvention While at Orbimed, he drove proprietary deal sourcing, diligence, negotiation, and investment decisions for growth stage companies and determined valuation ranges for companies and products with a focus on technology platform value, commercial potential, and binary catalysts such as clinical and regulatory milestones. Copyright 2001-2023 RA Capital Management, L.P. Maryann received her Bachelor of Science in English from Northeastern University. Peter also leads the firms engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. Michaels primary responsibility at RA Capital is to start and maintain relationships with current and potential investors. Sophie is Chief Medical Officer at Enara Bio, a company focused on novel targets for cancer immune therapy drug discovery. Fuads primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. FORBES estimates that Roivant is worth $3.5 billion, making its Millennial founder's 20% or so stake worth some $700 million. Jon Lundt is a Senior Associate within the TechAtlas division of RA Capital Management. Milind Deshpande is a Venture Partner at RA Capital, and President & CEO of Nayan Therapeutics, a RA Capital portfolio company. He also provided additional system administration and training for the desktop engineering team. Previously in his career, he served as Associate General Counsel at Millennium Pharmaceuticals (now Takeda Oncology) where he built the legal department and led internal legal activities supporting several transformative pharmaceutical partnerships, a substantial global patent estate, and the companys IPO. Previously, was a Research Analyst in the Kauwe lab at Brigham Young University. Vanderpump Rules' Peter Madrigal's Age. Prithviraj works on both public and private investments with a focus on Healthcare, Technology, and Services. He is active in both public and private investments In biotechnology areas as diverse as drugs, medical devices, diagnostics, and life science tools. Under his leadership, Therapeutics Alliances advanced 40+ projects, including 11 projects partnered with biopharma or new startups such as Repare Therapeutics and GliXogen Therapeutics. Erich holds a BA in English Literature and Language from Harvard University and a PhD in Microbiology from the University of North Carolina, Chapel Hill. Alex has a BA with a triple-major in Finance, Economics, and Math from UMass Lowell. Nadim completed his BS in Biology at Stony Brook University, received his PhD with Distinction in Microbiology at Columbia University, and was an NRSA Postdoctoral Fellow studying the cell biology of HCV in the laboratory of Nobel Prize winner Charles M. Rice at the Rockefeller University. Sarah began her legal career with Foley, Hoag, & Eliot LLP. Michael has also previously held the position of Vice President and General Manager at Thomson Medstat (now part of IBM Watson Health), as well as held management roles at Immusol, a San Diego-based biotechnology company, HealthAllies, an organization created to provide discretionary medical benefits to the cash-pay market, and Da Vita, a national provider of dialysis services. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Prior to CVS Health, Prithviraj was a Senior Research Associate at the Gerson Lehrman Group. Peter Kolchinsky Net Worth (2023) | wallmine Sri Mahendra is a Senior Software Engineer at RA Capital Management. Most recently, she was as an Entrepreneur-in-Residence at RA Ventures and was a Scientific Co-Founder and Associate Director of Corporate Development at Athenen Therapeutics (merged into Eliem Therapeutics; ELYM). Kates primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Prior to Avilar, Mr. Grau was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). After joining RA Ventures as Chief Development Officer, Ed built the development team, oversaw development of six compounds from discovery-stage through to clinical-stage, and led the formation of several new companies, including Lusaris Therapeutics. Cosmas Giallourakis is a Venture Partner at RA Ventures, focusing on new company creation. Scott joins RA Ventures (RAVen) as Venture Partner and will be focusing on new company creation. "He'll be 86 by the time it's over," said a woman in her 50s, noting the age Biden would be if he wins re-election and serves out a second term. In this episode Peter speaks with Dr. Wayne Shreffler, Director of the Food Allergy Center at Massachusetts General Hospital & Division Chief of Pediatric Allergy and Immunology at MassGeneral Hospital for Children. Prior to joining Aberdeen, Eric worked as a Compliance Examiner at the US Securities and Exchange Commission. Cosmass academic research has been published in journals such as Cell, Science, and Nature. Emorys primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. By continuing, you accept the use of these cookies. Megan has a BS in Microbiology & Cell Science from University of Florida. Anthonys primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Phi Thach is an Executive Assistant at RA Capital Management. As President, U.S. Pharmaceuticals at Bayer, he directed a multi-billion-dollar portfolio of products across multiple therapeutic areas (cardiovascular disease, hematology, neurology, oncology, and women's health). He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in . Peter Kolchinsky, PhD '01, is a founder, Portfolio Manager, and Managing Director at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences. Her doctoral research investigated the folding and aggregation of gamma-crystallins associated with cataract formation. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University. Benjamin Hicks is a Venture Operations Associate at RA Capital Management. Joey ONeill is an Investor Services Associate at RA Capital Management. Lucas previously held Law Clerk positions at The Community Builders, Inc. and at Nixon Peabody LLP. Craig holds a BA in Political Science from Bridgewater State College and a JD from Boston College Law School. Prior to PwC, Brendan worked as Senior Tax Analyst for Highfields Capital Management LP and held tax and accounting positions at Citi and Investors Bank & Trust / State Street. Ben previously worked as a Research Assistant in a Neuroinflammation lab at Brigham and Womens Hospital/Harvard Medical School, and was an Internet Application Developer at the Gallup Organization. The market worked. Tess Cameron is a Principal on the Investment Team at RA Capital Management. He is co-founder and CEO of Clear Creek Bio, an RA Capital portfolio company. Jaimie has a BS in Marketing Management from Coastal Carolina University. Milind has co-authored more than 80 scientific articles, is co-inventor on 30 patents, and is a frequent speaker at international scientific conferences. Cristina has nearly a decade of experience in the biotech and life sciences industries. Before Energetic, she was Head of Carbon Strategic Partnerships at Indigo Ag, where she led external innovation focused on solutions that minimize or sequester agricultural GHG emissions and deliver additional environmental, social, and economic co-benefits. Previously, Jake covered solid tumor oncology landscapes. He is also an active member of the Big Brothers of Massachusetts Bay program. Michael Sherman is a Venture Partner at RA Ventures. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. Ramin Farzaneh-Far is a Venture Partner at RA Capital where he works closely with RAs Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Rye Lane to Peter Pan & Wendy: the seven best films to watch on TV this Candice Galvez is an Executive Assistant at RA Capital Management. from Harvard College and an M.B.A. from Harvard Business School. Erich Scheller is the Director of the TechAtlas division of RA Capital Management. RA Capital | Team James holds a BS in Journalism from Boston University and a JD from Boston College Law School. Brian previously worked at the Kraft Group LLC, where he led their system admin, network, and desktop engineering groups. Prior to RA, Laura was a Principal at MP Healthcare Venture Management. Garrett has worked cross-functionally across the landscape of in vivo and ex vivo genetic medicine modalities, often at the interface of payload design, platform research and manufacturing, IND-enabling activities, bioanalytical and computational biology, and strategy. Sarah teaches a course at Harvard Law School on venture capital fund formation. Mario is responsible for partnering with several of our portfolio companies as Board Member or Technical Advisor. He holds a Masters degree in Software Engineering from Brandeis University and a BA in Psychology from Providence College. Laura is an Executive Assistant at RA Capital Management. Mark Boshar is a Venture Partner at RA Ventures (RAVen), focusing on new company creation. Dings primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Prior to IGEN Cony worked for Corning in the US and in Europe. Raj holds a BA from Cornell University, where he majored in Chemistry. Finally, they made it to the Boston. Meredith is a Senior Research Assistant at RA Capital Management. in Life Science from National Taiwan University, M.S. Prior to GHP, Lorena served as an Assurance Senior at EY. Previously, Michael worked closely with the Investment Team, to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Emory has a BS from Vassar College and an MD from the Harvard-MIT Health, Science, Technology Program at Harvard Medical School. Eric holds a MAcc from Bentley University and a BS in Finance from George Mason University. Abhishek's primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. In addition, Cosmas has co-founded companies including Design Pharma (synthetic bio) and a company in stealth focused on RNA based genetic medicines. RA Capital and CEO of Arcuate Therapeutics. He holds a BA from Cornell University and a PhD in Virology from Harvard University. Ed holds a PhD in neuroscience from the University of California Berkeley, an MS in psychology from Villanova University, and a BA from La Salle University. Joey previously served as Private Client Associate at Bernstein Private Wealth Management. Biotech's Dulcius Ex Asperis: The Way Through This Downturn Joshs primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. MarketScreener: Created by Investors for Investors! Brian Lewandowski is an Analyst on the Investment Team at RA Capital Management. Anurag holds a BSE in Biomedical Engineering and a BS in Economics from Duke University. Michael Gillespie is an Analyst on the Venture Team at RA Capital Management. Most recently, he was Chief Technology Officer at Vor Bio where he built the technical operations team responsible for process development, analytical development, supply chain and manufacturing support of a CRISPR gene-edited HSPC product and oversaw the companys CAR-T efforts. In his Venture role, Mario is focusing on early-stage investment and company creation. Prior to her stint coaching, she received her BS in Psychology with a Minor in History from Union College in NY. Prior to RA, Henry gained experience as an Investment Banking Analyst at SVB Leerink. Matthew Hammond is a Principal on the Investment Team at RA Capital Management. In his most recent role as Entrepreneur In Residence at RA Ventures (RAVen), Michael worked closely with the Venture Team to evaluate drug discovery platforms and initiate novel therapeutic programs. Prior to joining RA, Emily was Chief Business Officer of Prevail Therapeutics from the companys inception in 2017 until its acquisition by Eli Lilly in 2021. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and reasonably well-trained dog. Rezs primary responsibility is to lead early-stage private investments in, and oversee the creation of, new companies developing therapeutics and other medical technologies. Abhishek has a BS in Bioproducts and Biosystems Engineering and a BS in Chemistry from University of Minnesota, Twin Cities. Kolchinsky is a founder and Managing Partner of RA Capital Management, L.P., a multi-stage investment manager which is dedicated to evidence-based investing in healthcare and life science companies that are developing drugs, medical devices, and diagnostics, where he has worked since 2001. Garrett received a BS with honors from the California Institute of Technology while publishing his first paper with Dr. Paul H. Patterson, holds a PhD in Immunology from Stanford University, where he studied hematopoietic stem and progenitor cells with Dr. Irving L. Weissman, and completed his post-doctoral training at Childrens Hospital Boston/Harvard Medical School studying ES/iPSC specification to the hematopoietic fate with Dr. George Q. Daley. Tom has more than nine years of operations experience. She also gained administrative and client services experience in roles she held at Life Time Athletic, EF Education First, and at Beth Israel Deaconess Hospital ICU. Prior to this, Gerald was Director of Scientific Operations for RA Capital. Prior to her Managing Director role at NVF, Nandita held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah Global Program Team, helping to bring this novel cell therapy to market. Christys primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. James is admitted to practice law in the Commonwealth of Massachusetts. Sonia Kartha is an Associate with the TechAtlas division of RA Capital Management. Prior to Vor, Sadik served as Executive Director at Kite Pharma and led the development of manufacturing processes for autologous CAR-T and TCR-based cell therapies. Drew has a BS in Chemical Engineering from University of Virginia and a PhD in Chemical Engineering from Massachusetts Institute of Technology. Anthony has a BS in Molecular and Cellular Biology from University of Arizona and a PhD in Genetics and Molecular Biology from University of North Carolina at Chapel Hill. Tyler holds a BA in Finance from the University of Massachusetts, Amherst and a certificate in Interactive Design from Rhode Island School of Design. In that role, Joel led teams responsible for advancing more than 40 compounds into clinical development, including Sprycel (dasatinib), which he co-invented. Brian has more than ten years of buy-side experience covering the healthcare sector, with a focus on biotech, pharma, and specialty pharma. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Ben holds a BS in Biology and an MS in Virology from the University of Nebraska, Lincoln, and a PhD in Cancer Biology from the Tufts University School of Medicine. Adam was most recently President, CEO and member of the Board of Directors of Rodin Therapeutics until its acquisition by Alkermes in 2019.